Adherence to Guidelines: Evaluation of Opioid Usage According to the Who Step Ladder Guideline in Inpatient Cancer Patients
Abstract
WHO analgesic step-ladder is still the mainstay guideline in managing pain. However, pain in cancer patients developed from a more complex pathomechanism, hence requiring special consideration. This study aimed to compare the visual analog scale (VAS) of opioid and non-opioid analgesia in treating cancer patients and evaluate its rationality with World health organization (WHO) analgesic step-ladder.Method: A single-center, cross-sectional and analytic-descriptive study conducted in our centre. The population of this study comprised all cancer patients receiving analgesic therapy. The sampling technique used was consecutive, involving patients who met the inclusion and exclusion criteria. A total of 62 patients were included in the study as the research sample. Pain level was measured before and between 12 – 24 hours after analgesia, using VAS and divided into mild, moderate, or severe. Analgesic regimens were documented, and the daily opioid dose was presented on milligram morphine equivalent. Statistical analysis was performed to compare the variables before and after analgesia using the Wilcoxon signed-rank test, with a p-value <0.05 considered statistically significant.Result: From 62 patients, 46 subjects were included. Median milligram morphine equivalent was 20 mg (0-60). While the majority of patients experienced mild pain, 13 patients (27.7%) had moderate to severe pain. The most commonly used opioid was intravenous fentanyl, administered to 13 patients (27.7%), with a median morphine equivalent dose of 20 mg/day. Only 1 patient received opioid rationally according to WHO. Both non-opioid and opioid group had significant VAS differences before and after therapy (p = 0.014 and p <0.001). In both non-opioid and opioid groups, there were differences of VAS scores in the post-administration of analgesic, but these differences were not statistically significant (p= 0.885). Conclusion: The study concludes that, although most analgesics were not administered in accordance with the WHO step-ladder guideline, both opioid and non-opioid analgesics were effective in reducing pain in palliative cancer patients.
References
Anekar, A. A., Hendrix, J. M., & Cascella, M. (2023). WHO Analgesic Ladder. Journal of the Royal College of Physicians of Edinburgh, 38(3), 284. https://doi.org/10.1007/978-3-642-28753-4_102537
Ballantyne, J. C., Kalso, E., & Stannard, C. (2016). WHO analgesic ladder: a good concept gone astray. BMJ (Clinical Research Ed.), 352. https://doi.org/10.1136/BMJ.I20
Bandieri, E., Romero, M., Ripamonti, C. I., Artioli, F., Sichetti, D., Fanizza, C., Santini, D., Cavanna, L., Melotti, B., Conte, P. F., Roila, F., Cascinu, S., Bruera, E., Tognoni, G., & Luppi, M. (2016). Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(5), 436–442. https://doi.org/10.1200/JCO.2015.61.0733
Dalal, S., & Bruera, E. (2019). Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era. Https://Doi.Org/10.1200/EDBK_100020, 39, 24–35. https://doi.org/10.1200/EDBK_100020
Fallon, M., Dierberger, K., Leng, M., Hall, P. S., Allende, S., Sabar, R., Verastegui, E., Gordon, D., Grant, L., Lee, R., McWillams, K., Murray, G. D., Norris, L., Reid, C., Sande, T. A., Caraceni, A., Kaasa, S., & Laird, B. J. A. (2022a). An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Annals of Oncology, 33(12), 1296–1303. https://doi.org/10.1016/J.ANNONC.2022.08.083
Fallon, M., Dierberger, K., Leng, M., Hall, P. S., Allende, S., Sabar, R., Verastegui, E., Gordon, D., Grant, L., Lee, R., McWillams, K., Murray, G. D., Norris, L., Reid, C., Sande, T. A., Caraceni, A., Kaasa, S., & Laird, B. J. A. (2022). An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Annals of Oncology, 33(12), 1296–1303. https://doi.org/10.1016/J.ANNONC.2022.08.083
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018). Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines†. Annals of Oncology, 29, iv166–iv191. https://doi.org/10.1093/ANNONC/MDY152
Fallon, M. T., Caraceni, A., Laird, B. J. A., & Kaasa, S. (2023). Reply to the Letter to the Editor “A simple way of doing the complex but utmost important things: cancer pain management” by S. Singhal, M. Verma and D. Kukreja. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 34(5), 496–497. https://doi.org/10.1016/j.annonc.2023.02.005
Glare, P., Aubrey, K., Gulati, A., Lee, Y. C., Moryl, N., & Overton, S. (2022). Pharmacologic Management of Persistent Pain in Cancer Survivors. Drugs, 82(3), 275–291. https://doi.org/10.1007/S40265-022-01675-6
James, A., & Williams, J. (2020). Basic Opioid Pharmacology — An Update. British Journal of Pain, 14(2), 115–121. https://doi.org/10.1177/2049463720911986
Kapoor, R., Saxena, A. K., Vasudev, P., Sundriyal, D., & Kumar, A. (2021). Cancer induced bone pain: current management and future perspectives. Medical Oncology (Northwood, London, England), 38(11). https://doi.org/10.1007/S12032-021-01587-7
Mestdagh, F., Steyaert, A., & Lavand’homme, P. (2023). Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques. Current Oncology, 30(7), 6838. https://doi.org/10.3390/CURRONCOL30070500
Rauenzahn, S., Sima, A., Cassel, B., Noreika, D., Gomez, T. H., Ryan, L., Wolf, C. E., Legakis, L., & Del Fabbro, E. (2017). Urine drug screen findings among ambulatory oncology patients in a supportive care clinic. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 25(6), 1859–1864. https://doi.org/10.1007/S00520-017-3575-1
Snijders, R. A. H., Brom, L., Theunissen, M., & van den Beuken-van Everdingen, M. H. J. (2023). Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers, 15(3). https://doi.org/10.3390/CANCERS15030591
Wantonoro, Suprayitno, E., & Suryaningsih, E. K. (2021). The Overview of Pain in Cancer Patients. 90–95. https://doi.org/10.2991/AHSR.K.210127.020
Yennurajalingam, S., Arthur, J., Reddy, S., Edwards, T., Lu, Z., Rozman De Moraes, A., Wilson, S. M., Erdogan, E., Joy, M. P., Ethridge, S. D., Kuriakose, L., Malik, J. S., Najera, J. M., Rashid, S., Qian, Y., Kubiak, M. J., Nguyen, K., Wu, J., Hui, D., & Bruera, E. (2021). Frequency of and Factors Associated With Nonmedical Opioid Use Behavior Among Patients With Cancer Receiving Opioids for Cancer Pain. JAMA Oncology, 7(3), 404–411. https://doi.org/10.1001/JAMAONCOL.2020.6789
Zheng, J., Huang, Y., He, J., Zhou, H., Liu, T., Huang, J., Shi, M., Zhao, Y., Fang, W., Yang, Y., & Zhang, L. (2024). Trends in pain undertreatment among lung cancer patients at the EOL: Analysis of urban city medical insurance data in China. Thoracic Cancer, 15(9), 693. https://doi.org/10.1111/1759-7714.15240.
Copyright (c) 2025 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
